期刊
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
卷 35, 期 5, 页码 718-723出版社
SAGE PUBLICATIONS INC
DOI: 10.1038/jcbfm.2015.17
关键词
diabetes; DPP-4 inhibitors; exendin-4; GLP-1; liraglutide; neuroprotection; stroke
资金
- Novo Nordisk foundation
- European Foundation for the Study of Diabetes
- Diabetesfonden
- Swedish Heart and Lung Foundation
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Diabetes Research & Wellness Foundation
- foundation Magnus Bergvall
- foundation Axel and Signe Lagerman's Donation
- foundation Loo and Hans Osterman
- foundation Ahlen
- foundation STROKE Riksforbundet
- foundation Tornspiran
- foundation Gamla Tjanarinnor
- foundation Syskonen Svensson
- Fighting Stroke Project (Uppdrag Besegra Stroke) by Swedish Heart and Lung foundation
- Karolinska Institutet
During the past decades, candidate drugs that have shown neuroprotective efficacy in the preclinical setting have failed in clinical stroke trials. As a result, no treatment for stroke based on neuroprotection is available today. The activation of the glucagon-like peptide 1 receptor (GLP-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. In addition, clinical studies are currently ongoing. Herein, we review this emerging research field and discuss the next milestones to be achieved to develop a novel antistroke therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据